New Market Study Published: Spain Pharmaceuticals & Healthcare Report Q1 2013
BMI View: The move towards increased out-of-pocket drug expenditure (via the de-reimbursement of medicines and increased medicine co-payments) will put more pressure on the finances of the Spanish population. Double-digit unemployment, deflating asset prices (particularly real estate) and rising inflation (which is eating into real wages) have already significantly weakened final demand and in addition to the drug price erosion mechanisms employed by the government, will significantly restrict drug companies' revenue-earning opportunities.
View full press release